News
KYNB
7.01
-1.27%
-0.09
Weekly Report: what happened at KYNB last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at KYNB last week (0316-0320)?
Weekly Report · 03/23 09:16
FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven
TipRanks · 03/18 00:05
Kyntra Bio Q4 And FY25 Revenue Declines; On Track For Phase 2 Trial Analysis Of FG-3246 In H2,2026
NASDAQ · 03/17 10:26
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio
TipRanks · 03/17 10:16
Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points
TipRanks · 03/16 22:55
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
The Motley Fool · 03/16 22:08
Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale
Reuters · 03/16 20:25
*Kyntra Bio: Phase 2 Monotherapy Trial of FG-3246 Actively Enrolling and Remains on Track for Interim Analysis in 2H
Dow Jones · 03/16 20:22
FibroGen GAAP EPS of -$3.51 beats by $0.37, revenue of $1.27M misses by $0.4M
Seeking Alpha · 03/16 20:04
Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate
Benzinga · 03/16 20:03
Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million
Reuters · 03/16 20:03
*Kyntra Bio Has Cash, Cash Equivalents, Investments, and Accounts Receivable of $109.4 M, Providing Cash Runway Into 2028
Dow Jones · 03/16 20:03
*Kyntra Bio 4Q Loss $14.2M >KYNB
Dow Jones · 03/16 20:03
*Kyntra Bio 4Q Rev $1.28M >KYNB
Dow Jones · 03/16 20:03
KYNTRA BIO INC - Q4 EPS $-3.51
Reuters · 03/16 20:02
KYNTRA BIO INC - PHASE 2 FG-3246 TRIAL IN MCRPC ENROLLING, INTERIM ANALYSIS EXPECTED 2H 2026
Reuters · 03/16 20:02
*Kyntra Bio 4Q Loss/Shr $3.51 >KYNB
Dow Jones · 03/16 20:02
Press Release: Kyntra Bio Reports Fourth Quarter -2-
Dow Jones · 03/16 20:02
Kyntra Bio: Q4 Earnings Snapshot
Barchart · 03/16 15:20
More
Webull provides a variety of real-time KYNB stock news. You can receive the latest news about KYNTRA BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.